Gamma-irradiation of serum for the inactivation of adventitious contaminants

PDA Journal of Pharmaceutical Science and Technology

Volumn 64, Issue 5, 2010, Pages 432-435

  Gauvin, Gay ^a   Nims, Raymond ^b  

^a AMGEN INC   (United States)

^b RMC Pharmaceutical Solutions Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVENTITIOUS CONTAMINANT; ANIMAL CELL; ANIMAL CELL CULTURE; CACHE VALLEY BUNYAVIRUS; CALICIVIRUS; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; COW; DRUG MANUFACTURE; DRUG SAFETY; GAMMA IRRADIATION; MYCOPLASMA; NONHUMAN; PARVOVIRUS; PICORNAVIRUS; POLYOMA VIRUS; RADIATION DOSE; REOVIRUS; RISK MANAGEMENT; SERUM; VIRAL CONTAMINATION; VIRUS; VIRUS INACTIVATION; ANIMAL; HUMAN; PARVOVIRIDAE; RADIATION RESPONSE; VIRUS INFECTION;

BIOLOGICAL PRODUCT;

ANIMALS; BIOLOGICAL PRODUCTS; HUMANS; MYCOPLASMA; PARVOVIRUS; SERUM; VIRUS DISEASES; VIRUS INACTIVATION; VIRUSES;

EID: 78149293179     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. US FDA. Points to Consider in the Characterization of Cell Lines Used to Produce Biologics, FDA/CDER, 1993.
2. International Conference on Harmonisation. ICH Q5A (R1). Quality of Biotechnological Products: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. CPMP/ICH/295/95, October 1997.
3. EMEA. Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products. /410/01 Rev. 2 October 2003.
4. Nims, R. Detection of adventitious viruses in biologicals - a rare occurrence. Dev. Biol. 2006, 123, 153-164. (Pubitemid 43210364)
5. Kerr, A.; Nims, R. Adventitious viruses detected in biopharmaceutical bulk harvest samples over a 10 year period. PDA J. Pharm. Sci. Technol. 2010, (this volume).
6. Chen, D.; Nims, R.; Dusing, S.; Miller, P.; Luo, W.; Quertinmont, M.; Parekh, B.; Poorbaugh, J.; Boose, J. A.; Atkinson, E. M. Root cause investigation of a viral contamination incident occurred during master cell bank (MCB) testing and characterization - a case study. Biologicals 2008, 36 (6), 393-402.
7. Dehghani, H.; Rasmussen, B.; Fung, V.; Piper, R.; Gosink, J.; Weaver, B.; Reddy P. Case studies of mycoplasma contamination in CHO cell cultures. Proceedings from the PDA Workshop on Mycoplasma Contamination by Plant Peptones; Parenteral Drug Association: Bethesda, MD, 2007; pp 53-59.
8. Sofer, G. Virus inactivation in the 1990s - and into the 21st century. Part 4, Culture media, biotechnology products, and vaccines. Biopharm Int. 2003, 16 (1), 50-57. (Pubitemid 36330097)
9. Schuurman, R.; van Steenis, B.; van Strien, A.; van der Noordaa, J.; Sol, C. Frequent detection of bovine polyomavirus in commercial batches of calf serum by using the polymerase chain reaction. J. Gen. Virol. 1991, 72 (11), 2739-2745.
10. rd ed. Griffin: London, 1978; pp 394-401.
11. Chapter 2.6.7. Mycoplasmas. European Pharmacopoeia; 5th ed. (5.4), 2006.
12. Willkommen, H.; Scheiblauer, H.; Löwer, J. Serum and serum substitutes. Virus safety by inactivation or removal. Dev. Biol. Stand. 1999, 99, 131-138.
13. Boose, J. A.; Lister, D. C.; Sofer G. Virus inactivation in the 1990s - and into the 21st century. Part 6, Inactivation methods grouped by virus. Biopharm Int. 2003, 16 (4), 42-68. (Pubitemid 36330097)
14. Bender, E.; Fritzche, J.; Bär, M.; Nordheim, W. The inactivation of mycoplasmas and bacteria in calf serum by 60Co gamma rays (in German). Arch. Exp. Veterinarmed. 1989, 43 (5), 783-788.